For years, the dominant theory behind Alzheimer’s disease has centered on sticky protein clumps — amyloid-beta plaques — as the primary culprit. Drug after drug targeting those plaques has failed in clinical trials. Patients kept declining. The field needed a new direction.
Now researchers at Scripps Research in La Jolla have found one. Their discovery, published June 5, shifts the focus from the clumps themselves to the inflammatory chaos they set off inside the brain. At the heart of that chaos is a protein called STING — a molecule that normally acts as an alarm system against infection. In Alzheimer’s, that alarm gets stuck in the “on” position.
What the team found is a chemical modification — a kind of molecular toggle switch — that locks STING into a hyperactive state. Instead of sounding a brief alert, it pumps out inflammatory signals nonstop. That chronic inflammation destroys the synaptic connections between neurons. And it’s the loss of those connections, not the plaques themselves, that correlates most directly with cognitive decline.
The trigger for this runaway inflammation comes from the very proteins long associated with Alzheimer’s: amyloid-beta and alpha-synuclein. They can flip the switch on STING. Once flipped, the process becomes self-perpetuating. More inflammation leads to more damage, which leads to more inflammation.
But the Scripps team, led by neurologist Stuart Lipton, identified something critical: the modification happens at a single building block on the STING protein, a site called cysteine 148. Block that one site in mice, and the harmful overactivation quieted down. Normal immune defenses stayed intact. That precision matters. Broad anti-inflammatory drugs have been tried in Alzheimer’s before. They tend to suppress the entire immune system, which can do more harm than good.
This approach is different. It targets only the pathological form of STING — the stuck switch — leaving the normal infection-fighting function alone.
There are external factors at play too. The researchers noted that aging, air pollution, and even wildfire smoke can raise levels of nitric oxide in the brain. Nitric oxide is what drives the chemical change on STING. So the same molecular mechanism that gets triggered by protein clumps can also be fueled by environmental exposure. That connects Alzheimer’s risk to something as mundane as the air people breathe.
The finding offers a plausible explanation for why amyloid-focused trials have been disappointing. If the real driver of cognitive decline is inflammation triggered by those clumps — but not the clumps themselves — then dissolving the plaques after the inflammatory cycle is already running may be too little, too late. The switch has already been flipped.
Lipton’s team is now working on developing small molecules that can block the modification at cysteine 148. The work is still in early stages. The results in mice are promising, but translating that into a drug for humans is a long road. Still, the logic is cleaner than what came before. Target the mechanism that sustains the damage, not just the debris that started it.
Alzheimer’s affects millions worldwide. There is no cure. The few treatments that exist offer modest symptom relief at best. A shift toward addressing neuroinflammation as a primary driver, rather than a side effect, marks a real change in thinking. This discovery gives that shift a concrete molecular target.
